The Supreme Court will review the constitutionality of the Affordable Care Act's no-cost preventive care coverage of cancer ...

Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...

Two-day symposium in Riyadh, Saudi Arabia brings together leading oncology professionals from across the MENA region to review updated treatment recommendations. RIYADH, Saudi Arabia, Jan.

A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate ...

Roughly one in six men will be diagnosed with prostate cancer at some point in their lives, but these cancers usually aren't life-threatening. Most newly diagnosed men have Grade Group 1 prostate ...

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson's lab at QUT in 'Aggressive Variant' prostate ca ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

Ambry Genetics, a leader in clinical genomic testing, today announced its contribution to a study published in Nature that significantly advances our understanding of BRCA2 gene variants. As the ...